Association between subfoveal choroidal thickness and prognoses after anti-vascular endothelial growth factor therapy in myopic choroidal neovascularization

Purpose: The aim of this study was to investigate subfoveal choroidal thickness (SFCT) changes following intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy and to identify SFCT and clinical parameters associated with functional anatomical prognoses in eyes with myopic choroidal neovascularization (mCNV). Methods: Forty-five pathologic myopia patients with unilateral mCNV (45 eyes) were enrolled in the study. All patients were treated with a single intravitreal injection of bevacizumab or ranibizumab by Pro Re Nata regimen. All subjects were evaluated by Spectral domain optical coherence tomography (SD-OCT) at baseline, one month, three months, and final visit after treatment. Results: Anti-VEGF therapeutics revealed significantly improved best-corrected visual acuity (BCVA), significantly decreased central foveal thickness (CFT), and greatest linear dimension (GLD) (all P < 0.05). SFCT revealed a significant decrease (P < 0.05) after anti-VEGF treatment. In multivariate regression analysis, baseline BCVA and recurrence associated significantly with final BCVA (P < 0.001 and P = 0.002, respectively). Baseline GLD and recurrence were associated significantly with final GLD (P = 0.001, respectively). In generalized linear model (GLM) analyses, number of injections was associated with recurrence (P = 0.001). However, SFCT was not associated with final BCVA, GLD, and number of injections. Conclusion: Anti-VEGF regimen was proven to be effective on mCNV, probably arousing significant changes in choroidal thickness. However, SFCT was not associated with functional and anatomical prognoses.